ivospemin

Ivospemin is a **small molecule, subcutaneously administered polyamine analogue** structurally related to spermine and formally known as SBP-101. It is designed to inhibit polyamine biosynthesis and induce polyamine catabolism, thereby depleting intracellular polyamine pools critical for the growth and proliferation of cancer cells. Ivospemin acts primarily through modulation of polyamine metabolic enzymes. Preclinical and early clinical trials report efficacy in pancreatic and ovarian cancers, especially in platinum-resistant ovarian and metastatic pancreatic ductal adenocarcinoma (PDA). In clinical studies, ivospemin improved median overall survival and objective response rates when combined with standard of care (e.g., gemcitabine and nab-paclitaxel). The drug is being investigated by Panbela Therapeutics, often in collaboration with academic centers like Johns Hopkins. Its evaluated indications include first-line metastatic pancreatic cancer, ovarian cancer, multiple myeloma, and prevention of colorectal cancer, with ongoing studies in relevant populations. Ivospemin is under advanced clinical evaluation (up to phase 3) as monotherapy and in combination therapy settings[1][2][4][5][6][7][8].

Other names

diethyl-dihydroxy-homospermine1,14-bis(ethylamino)-5,10-dihydroxytetradecane